Synucleinopathies: Where we are and where we need to go.
Parkinson's disease
alpha-synuclein
dementia Lewy bodies
multiple system atrophy
neurodegeneration
synucleinopathies
toxicity
Journal
Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
07
11
2019
revised:
07
01
2020
accepted:
08
01
2020
pubmed:
21
1
2020
medline:
29
10
2020
entrez:
21
1
2020
Statut:
ppublish
Résumé
Synucleinopathies are a group of disorders characterized by the accumulation of inclusions rich in the a-synuclein (aSyn) protein. This group of disorders includes Parkinson's disease, dementia with Lewy bodies (DLB), multiple systems atrophy, and pure autonomic failure (PAF). In addition, genetic alterations (point mutations and multiplications) in the gene encoding for aSyn (SNCA) are associated with familial forms of Parkinson's disease, the most common synucleinopathy. The Synuclein Meetings are a series that has been taking place every 2 years for about 12 years. The Synuclein Meetings bring together leading experts in the field of Synuclein and related human conditions with the goal of discussing and advancing the research. In 2019, the Synuclein meeting took place in Ofir, a city in the outskirts of Porto, Portugal. The meeting, entitled "Synuclein Meeting 2019: Where we are and where we need to go", brought together >300 scientists studying both clinical and molecular aspects of synucleinopathies. The meeting covered a many of the open questions in the field, in a format that prompted open discussions between the participants, and underscored the need for additional research that, hopefully, will lead to future therapies for a group of as of yet incurable disorders. Here, we provide a summary of the topics discussed in each session and highlight what we know, what we do not know, and what progress needs to be made in order to enable the field to continue to advance. We are confident this systematic assessment of where we stand will be useful to steer the field and contribute to filling knowledge gaps that may form the foundations for future therapeutic strategies, which is where we need to go.
Substances chimiques
Biomarkers
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
433-454Informations de copyright
© 2020 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Références
Abati, E., Di Fonzo, A., & Corti, S. (2018). In vitro models of multiple system atrophy from primary cells to induced pluripotent stem cells. Journal of Cellular and Molecular Medicine, 22, 2536-2546. https://doi.org/10.1111/jcmm.13563
Abeyawardhane, D. L., Fernandez, R. D., Heitger, D. R., Crozier, M. K., Wolver, J. C., & Lucas, H. R. (2018). Copper induced radical dimerization of alpha-synuclein requires histidine. Journal of the American Chemical Society, 140, 17086-17094.
Anderson, J. P., Walker, D. E., Goldstein, J. M., De Laat, R., Banducci, K., Caccavello, R. J., … Diep, L. (2006). Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. The Journal of Biological Chemistry, 281, 29739-29752.
Baptista, M. J., O'Farrell, C., Daya, S., Ahmad, R., Miller, D. W., Hardy, J., … Cookson, M. R. (2003). Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. Journal of Neurochemistry, 85, 957-968.
Barbour, R., Kling, K., Anderson, J. P., Banducci, K., Cole, T., Diep, L., … Chilcote, T. J. (2008). Red blood cells are the major source of alpha-synuclein in blood. Neuro-degenerative Diseases, 5, 55-59. https://doi.org/10.1159/000112832
Bardien, S., Lesage, S., Brice, A., & Carr, J. (2011). Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. Parkinsonism & Related Disorders, 17(7), 501-508. https://doi.org/10.1016/j.parkreldis.2010.11.008.
Barrenschee, M., Zorenkov, D., Böttner, M., Lange, C., Cossais, F., Scharf, A. B., … Wedel, T. (2017). Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. Acta Neuropathologica Communications, 5, 1. https://doi.org/10.1186/s40478-016-0408-2
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011). alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 477, 107-110.
Beach, T. G., Adler, C. H., Lue, L. F., Sue, L. I., Bachalakuri, J., Henry-Watson, J., … Walker, D. G. (2009). Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathologica, 117, 613-634. https://doi.org/10.1007/s00401-009-0538-8
Bergeron, C., Petrunka, C., Weyer, L., & Pollanen, M. S. (1996). Altered neurofilament expression does not contribute to Lewy body formation. The American Journal of Pathology, 148, 267-272.
Bernstein, H. G., Johnson, M., Perry, R. H., LeBeau, F. E., Dobrowolny, H., Bogerts, B., & Perry, E. K. (2011). Partial loss of parvalbumin-containing hippocampal interneurons in dementia with Lewy bodies. Neuropathology: Official Journal of the Japanese Society of Neuropathology, 31, 1-10. https://doi.org/10.1111/j.1440-1789.2010.01117.x
Binolfi, A., Rasia, R. M., Bertoncini, C. W., Ceolin, M., Zweckstetter, M., Griesinger, C., … Fernandez, C. O. (2006). Interaction of alpha-synuclein with divalent metal ions reveals key differences: A link between structure, binding specificity and fibrillation enhancement. Journal of the American Chemical Society, 128, 9893-9901.
Blauwendraat, C., Nalls, M. A., & Singleton, A. B. (2019). The genetic architecture of Parkinson's disease. The Lancet Neurology, 19, 170-178. https://doi.org/10.1016/S1474-4422(19)30287-X
Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P. H., Habenstein, B., … Melki, R. (2013). Structural and functional characterization of two alpha-synuclein strains. Nature Communications, 4, 2575. https://doi.org/10.1038/ncomms3575
Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24, 197-211. https://doi.org/10.1016/S0197-4580(02)00065-9
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H., & Del Tredici, K. (2004). Stages in the development of Parkinson's disease-related pathology. Cell and Tissue Research, 318, 121-134. https://doi.org/10.1007/s00441-004-0956-9
Breda, C., Nugent, M. L., Estranero, J. G., Kyriacou, C. P., Outeiro, T. F., Steinert, J. R., & Giorgini, F. (2015). Rab11 modulates alpha-synuclein-mediated defects in synaptic transmission and behaviour. Human Molecular Genetics, 24, 1077-1091.
Burre, J., Sharma, M., & Sudhof, T. C. (2012). Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32, 15227-15242.
Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Sudhof, T. C. (2010). Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 329, 1663-1667. https://doi.org/10.1126/science.1195227
Butler, B., Saha, K., Rana, T., Becker, J. P., Sambo, D., Davari, P., … Khoshbouei, H. (2015). Dopamine transporter activity is modulated by alpha-synuclein. The Journal of Biological Chemistry, 290, 29542-29554.
Cairns, A. G., Vazquez-Romero, A., Mahdi Moein, M., Ådén, J., Elmore, C. S., Takano, A., … Schou, M. (2018). Increased brain exposure of an alpha-synuclein fibrillization modulator by utilization of an activated ester prodrug strategy. ACS Chemical Neuroscience, 9, 2542-2547. https://doi.org/10.1021/acschemneuro.8b00236
Caughey, B., & Lansbury, P. T. (2003). Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annual Review of Neuroscience, 26, 267-298.
Chandra, S., Chen, X., Rizo, J., Jahn, R., & Sudhof, T. C. (2003). A broken alpha -helix in folded alpha-synuclein. The Journal of Biological Chemistry, 278, 15313-15318.
Chen, R. H., Wislet-Gendebien, S., Samuel, F., Visanji, N. P., Zhang, G., Marsilio, D., … Tandon, A. (2013). alpha-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. The Journal of Biological Chemistry, 288, 7438-7449.
Chen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., … Friedland, R. P. (2016). Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Scientific Reports, 6, 34477. https://doi.org/10.1038/srep34477
Chutna, O., Gonçalves, S., Villar-Piqué, A., Guerreiro, P., Marijanovic, Z., Mendes, T., … Barral, D. C. (2014). The small GTPase Rab11 co-localizes with alpha-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity. Human Molecular Genetics, 23, 6732-6745.
Cole, N. B., Murphy, D. D., Grider, T., Rueter, S., Brasaemle, D., & Nussbaum, R. L. (2002). Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. The Journal of Biological Chemistry, 277, 6344-6352.
Colla, E., Coune, P., Liu, Y., Pletnikova, O., Troncoso, J. C., Iwatsubo, T., … Lee, M. K. (2012). Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32, 3306-3320.
Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Harper, J. D., Williamson, R. E., & Lansbury, P. T. Jr (2000). Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Annals of the New York Academy of Sciences, 920, 42-45.
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., … Cao, S. (2006). Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science, 313, 324-328. https://doi.org/10.1126/science.1129462
Covell, D. J., Robinson, J. L., Akhtar, R. S., Grossman, M., Weintraub, D., Bucklin, H. M., … Lee, V. Y. (2017). Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. Neuropathology and Applied Neurobiology, 43, 604-620.
Cullen, V., Lindfors, M., Ng, J., Paetau, A., Swinton, E., Kolodzeij, P., … Tyynela, J. (2009). Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Molecular Brain, 2, 5. https://doi.org/10.1186/1756-6606-2-5
Dahmene, M., Berard, M., & Oueslati, A. (2017). Dissecting the molecular pathway involved in PLK2 kinase-mediated alpha-synuclein-selective autophagic degradation. The Journal of Biological Chemistry, 292, 3919-3928.
Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., … McLean, P. J. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. Molecular Neurodegeneration, 7, 42. https://doi.org/10.1186/1750-1326-7-42
de Oliveira, R. M., Vicente Miranda, H., Francelle, L., Pinho, R., Szegö, É. M., Martinho, R., … Outeiro, T. F. (2017). The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biology, 15, e2000374. https://doi.org/10.1371/journal.pbio.2000374
Delenclos, M., Burgess, J. D., Lamprokostopoulou, A., Outeiro, T. F., Vekrellis, K., & McLean, P. J. (2019). Cellular models of alpha-synuclein toxicity and aggregation. Journal of Neurochemistry, 150, 566-576. https://doi.org/10.1111/jnc.14806
Devi, L., & Anandatheerthavarada, H. K. (2010). Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochimica Et Biophysica Acta, 1802, 11-19. https://doi.org/10.1016/j.bbadis.2009.07.007
Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., & Anandatheerthavarada, H. K. (2008). Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. The Journal of Biological Chemistry, 283, 9089-9100.
Di Maio, R., Barrett, P. J., Hoffman, E. K., Barrett, C. W., Zharikov, A., Borah, A., … Hastings, T. G. (2016). alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. Science Translational Medicine, 8, 342ra378.
Dijkstra, A. A., Voorn, P., Berendse, H. W., Groenewegen, H. J., Rozemuller, A. J., & van de Berg, W. D. (2014). Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 29, 1244-1251. https://doi.org/10.1002/mds.25952
Doorn, K. J., Moors, T., Drukarch, B., van de Berg, W., Lucassen, P. J., & van Dam, A. M. (2014). Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Acta Neuropathologica Communications, 2, 90.
Duffy, P. E., & Tennyson, V. M. (1965). Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson's disease. Journal of Neuropathology and Experimental Neurology, 24, 398-414.
Dugger, B. N., & Dickson, D. W. (2010). Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathologica, 120, 633-639. https://doi.org/10.1007/s00401-010-0739-1
Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, B. T., … Unni, V. K. (2011). Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 31, 14508-14520.
Ejlerskov, P., Rasmussen, I., Nielsen, T. T., Bergstrom, A. L., Tohyama, Y., Jensen, P. H., & Vilhardt, F. (2013). Tubulin polymerization-promoting protein (TPPP/p25alpha) promotes unconventional secretion of alpha-synuclein through exophagy by impairing autophagosome-lysosome fusion. The Journal of Biological Chemistry, 288, 17313-17335.
El-Agnaf, O., Overk, C., Rockenstein, E., Mante, M., Florio, J., Adame, A., … Masliah, E. (2017). Differential effects of immunotherapy with antibodies targeting alpha-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiology of Disease, 104, 85-96.
Eliezer, D., Kutluay, E., Bussell, R. Jr, & Browne, G. (2001). Conformational properties of alpha-synuclein in its free and lipid-associated states. Journal of Molecular Biology, 307, 1061-1073.
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., … Vekrellis, K. (2010). Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 30, 6838-6851.
Engelender, S., Kaminsky, Z., Guo, X., Sharp, A. H., Amaravi, R. K., Kleiderlein, J. J., … Dawson, V. L. (1999). Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nature Genetics, 22, 110-114.
Eusebi, P., Giannandrea, D., Biscetti, L., Abraha, I., Chiasserini, D., Orso, M., … Parnetti, L. (2017). Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis. Movement Disorders: Official Journal of the Movement Disorder Society, 32, 1389-1400.
Fares, M. B., Ait-Bouziad, N., Dikiy, I., Mbefo, M. K., Jovičić, A., Kiely, A., … Lashuel, H. A. (2014). The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells. Human Molecular Genetics, 23, 4491-4509.
Fayyad, M., Salim, S., Majbour, N., Erskine, D., Stoops, E., Mollenhauer, B., & El-Agnaf, O. M. A. (2019). Parkinson's disease biomarkers based on alpha-synuclein. Journal of Neurochemistry, 150, 626-636.
Feany, M. B., & Bender, W. W. (2000). A Drosophila model of Parkinson's disease. Nature, 404, 394-398. https://doi.org/10.1038/35006074
Ferreira, D. G., Temido-Ferreira, M., Vicente Miranda, H., Batalha, V. L., Coelho, J. E., Szegö, É. M., … Zerr, I. (2017). alpha-Synuclein interacts with PrP(C) to induce cognitive impairment through mGluR5 and NMDAR2B. Nature Neuroscience, 20, 1569-1579.
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., … Keshavarzian, A. (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE, 6, e28032. https://doi.org/10.1371/journal.pone.0028032
Fortin, D. L., Troyer, M. D., Nakamura, K., Kubo, S., Anthony, M. D., & Edwards, R. H. (2004). Lipid rafts mediate the synaptic localization of alpha-synuclein. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 24, 6715-6723.
Freundt, E. C., Maynard, N., Clancy, E. K., Roy, S., Bousset, L., Sourigues, Y., … Brahic, M. (2012). Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal transport. Annals of Neurology, 72, 517-524.
Friedman, L. G., Lachenmayer, M. L., Wang, J., He, L., Poulose, S. M., Komatsu, M., … Yue, Z. (2012). Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of alpha-synuclein and LRRK2 in the brain. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32, 7585-7593.
Fukuda, T., Takahashi, J., & Tanaka, J. (1999). Tyrosine hydroxylase-immunoreactive neurons are decreased in number in the cerebral cortex of Parkinson's disease. Neuropathology: Official Journal of the Japanese Society of Neuropathology, 19, 10-13. https://doi.org/10.1046/j.1440-1789.1999.00196.x
Gamache, J., Benzow, K., Forster, C., Kemper, L., Hlynialuk, C., Furrow, E., … Koob, M. D. (2019). Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice. Nature Communications, 10, 2479. https://doi.org/10.1038/s41467-019-10428-1
Ghio, S., Kamp, F., Cauchi, R., Giese, A., & Vassallo, N. (2016). Interaction of alpha-synuclein with biomembranes in Parkinson's disease-role of cardiolipin. Progress in Lipid Research, 61, 73-82.
Gitler, A. D., Chesi, A., Geddie, M. L., Strathearn, K. E., Hamamichi, S., Hill, K. J., … Lindquist, S. (2009). Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nature Genetics, 41, 308-315.
Goers, J., Manning-Bog, A. B., McCormack, A. L., Millett, I. S., Doniach, S., Di Monte, D. A., … Fink, A. L. (2003). Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry, 42, 8465-8471.
Goncalves, S., & Outeiro, T. F. (2013). Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy. Molecular Neurobiology, 47, 1081-1092. https://doi.org/10.1007/s12035-013-8406-x
Grassi, D., Howard, S., Zhou, M., Diaz-Perez, N., Urban, N. T., Guerrero-Given, D., … Lasmézas, C. I. (2018). Identification of a highly neurotoxic alpha-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 115, E2634-E2643.
Grozdanov, V., & Danzer, K. M. (2018). Release and uptake of pathologic alpha-synuclein. Cell and Tissue Research, 373, 175-182. https://doi.org/10.1007/s00441-017-2775-9
Guerreiro, P. S., Huang, Y., Gysbers, A., Cheng, D., Gai, W. P., Outeiro, T. F., & Halliday, G. M. (2013). LRRK2 interactions with alpha-synuclein in Parkinson's disease brains and in cell models. Journal of Molecular Medicine, 91, 513-522.
Guo, J. T., Chen, A. Q., Kong, Q., Zhu, H., Ma, C. M., & Qin, C. (2008). Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cellular and Molecular Neurobiology, 28, 35-47.
Guo, J. L., Covell, D. J., Daniels, J. P., Iba, M., Stieber, A., Zhang, B., … Lee, V. M. (2013). Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell, 154, 103-117.
Halliday, G. M., Li, Y. W., Blumbergs, P. C., Joh, T. H., Cotton, R. G., Howe, P. R., … Geffen, L. B. (1990). Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Annals of Neurology, 27, 373-385. https://doi.org/10.1002/ana.410270405
Hansson, O., Hall, S., Ohrfelt, A., Zetterberg, H., Blennow, K., Minthon, L., … Al-Hayani, A. (2014). Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research and Therapy, 6, 25.
Harding, A. J., Stimson, E., Henderson, J. M., & Halliday, G. M. (2002). Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain: A Journal of Neurology, 125, 2431-2445. https://doi.org/10.1093/brain/awf251
Heintz-Buschart, A., Pandey, U., Wicke, T., Sixel-Döring, F., Janzen, A., Sittig-Wiegand, E., … Wilmes, P. (2018). The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. Movement Disorders: Official Journal of the Movement Disorder Society, 33, 88-98. https://doi.org/10.1002/mds.27105
Hill-Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., … Knight, R. (2017). Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Movement Disorders: Official Journal of the Movement Disorder Society, 32, 739-749.
Hoffmann, A., Ettle, B., Bruno, A., Kulinich, A., Hoffmann, A. C., von Wittgenstein, J., … Schlachetzki, J. C. M. (2016). Alpha-synuclein activates BV2 microglia dependent on its aggregation state. Biochemical and Biophysical Research Communications, 479, 881-886. https://doi.org/10.1016/j.bbrc.2016.09.109
Holmes, B. B., DeVos, S. L., Kfoury, N., Li, M., Jacks, R., Yanamandra, K., … Diamond, M. I. (2013). Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proceedings of the National Academy of Sciences of the United States of America, 110, E3138-3147. https://doi.org/10.1073/pnas.1301440110
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., … Li, J.-Y. (2014). Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathologica, 128, 805-820. https://doi.org/10.1007/s00401-014-1343-6
Iannaccone, S., Cerami, C., Alessio, M., Garibotto, V., Panzacchi, A., Olivieri, S., … Perani, D. (2013). In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism and Related Disorders, 19, 47-52.
Ihse, E., Yamakado, H., van Wijk, X. M., Lawrence, R., Esko, J. D., & Masliah, E. (2017). Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Scientific Reports, 7, 9008. https://doi.org/10.1038/s41598-017-08720-5
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003). Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathologica, 106, 518-526. https://doi.org/10.1007/s00401-003-0766-2
Ishizawa, T., Mattila, P., Davies, P., Wang, D., & Dickson, D. W. (2003). Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. Journal of Neuropathology and Experimental Neurology, 62, 389-397. https://doi.org/10.1093/jnen/62.4.389
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H. A., … Saitoh, T. (1995). The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 14, 467-475.
Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G., & Goedert, M. (1998). Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. The Journal of Biological Chemistry, 273, 26292-26294.
Jiang, P., Gan, M., Yen, S. H., McLean, P. J., & Dickson, D. W. (2017). Impaired endo-lysosomal membrane integrity accelerates the seeding progression of alpha-synuclein aggregates. Scientific Reports, 7, 7690.
Jo, E., McLaurin, J., Yip, C. M., St George-Hyslop, P., & Fraser, P. E. (2000). alpha-Synuclein membrane interactions and lipid specificity. The Journal of Biological Chemistry, 275, 34328-34334.
Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., … Kremmer, E. (2000). Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 20, 6365-6373.
Kalia, L. V., Lang, A. E., Hazrati, L. N., Fujioka, S., Wszolek, Z. K., Dickson, D. W., … Alcalay, R. N. (2015). Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurology, 72, 100-105.
Karpowicz, R. J. Jr, Haney, C. M., Mihaila, T. S., Sandler, R. M., Petersson, E. J., & Lee, V. M. (2017). Selective imaging of internalized proteopathic alpha-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. The Journal of Biological Chemistry, 292, 13482-13497.
Katsuse, O., Iseki, E., Marui, W., & Kosaka, K. (2003). Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. Journal of the Neurological Sciences, 211, 29-35. https://doi.org/10.1016/S0022-510X(03)00037-6
Katzeff, J. S., Phan, K., Purushothuman, S., Halliday, G. M., & Kim, W. S. (2019). Cross-examining candidate genes implicated in multiple system atrophy. Acta Neuropathologica Communications, 7, 117. https://doi.org/10.1186/s40478-019-0769-4
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., … Shannon, K. M. (2015). Colonic bacterial composition in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 30, 1351-1360. https://doi.org/10.1002/mds.26307
Khalaf, O., Fauvet, B., Oueslati, A., Khalaf, O., Bruno, F. B., Oueslati, A., … Lashuel, H. A. (2014). The H50Q mutation enhances alpha-synuclein aggregation, secretion, and toxicity. The Journal of Biological Chemistry, 289, 21856-21876.
Killinger, B. A., & Kordower, J. H. (2019). Spreading of alpha-synuclein - relevant or epiphenomenon? Journal of Neurochemistry, 150, 605-611. https://doi.org/10.1111/jnc.14779
Killinger, B. A., Madaj, Z., Sikora, J. W., Rey, N., Haas, A. J., Vepa, Y., … Labrie, V. (2018). The vermiform appendix impacts the risk of developing Parkinson’s disease. Science Translational Medicine, 10, eaar5280.
Kim, C., Lv, G., Lee, J. S., Jung, B. C., Masuda-Suzukake, M., Hong, C. S., … Masliah, E. (2016). Exposure to bacterial endotoxin generates a distinct strain of alpha-synuclein fibril. Scientific Reports, 6, 30891.
Kim, S., Kwon, S. H., Kam, T. I., Panicker, N., Karuppagounder, S. S., Lee, S., … Shen, C. (2019). Transneuronal propagation of pathologic alpha-synuclein from the Gut to the brain models Parkinson's disease. Neuron, 103(627-641), e627.
Klucken, J., Poehler, A. M., Ebrahimi-Fakhari, D., Schneider, J., Nuber, S., Rockenstein, E., … Winkler, J. (2012). Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway. Autophagy, 8, 754-766.
Kontopoulos, E., Parvin, J. D., & Feany, M. B. (2006). Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human Molecular Genetics, 15, 3012-3023.
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008). Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine, 14, 504-506. https://doi.org/10.1038/nm1747
Kotzbauer, P. T., Tu, Z., & Mach, R. H. (2017). Current status of the development of PET radiotracers for imaging alpha synuclein aggregates in Lewy bodies and Lewy neurites. Clinical and Translational Imaging, 5, 3-14. https://doi.org/10.1007/s40336-016-0217-4
Kragh, C. L., Lund, L. B., Febbraro, F., Hansen, H. D., Gai, W. P., El-Agnaf, O., … Jensen, P. H. (2009). Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. The Journal of Biological Chemistry, 284, 10211-10222.
Kramer, M. L., & Schulz-Schaeffer, W. J. (2007). Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 27, 1405-1410.
Kubo, S., Nemani, V. M., Chalkley, R. J., Anthony, M. D., Hattori, N., Mizuno, Y., … Fortin, D. L. (2005). A combinatorial code for the interaction of alpha-synuclein with membranes. The Journal of Biological Chemistry, 280, 31664-31672.
Kuzuhara, S., Mori, H., Izumiyama, N., Yoshimura, M., & Ihara, Y. (1988). Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathologica, 75, 345-353. https://doi.org/10.1007/BF00687787
Lautenschlager, J., Stephens, A. D., Fusco, G., Ströhl, F., Curry, N., Zacharopoulou, M., … Pinotsi, D. (2018). C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nature Communications, 9, 712.
Lazaro, D. F., Pavlou, M. A. S., & Outeiro, T. F. (2017). Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease. Experimental Neurology, 298, 162-171. https://doi.org/10.1016/j.expneurol.2017.05.007
Lázaro, D. F., Rodrigues, E. F., Langohr, R., Shahpasandzadeh, H., Ribeiro, T., Guerreiro, P., … Outeiro, T. F. (2014). Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genetics, 10, e1004741. https://doi.org/10.1371/journal.pgen.1004741
Lee, H. J., Shin, S. Y., Choi, C., Lee, Y. H., & Lee, S. J. (2002). Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. The Journal of Biological Chemistry, 277, 5411-5417.
Lee, H. J., Suk, J. E., Bae, E. J., & Lee, S. J. (2008a). Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochemical and Biophysical Research Communications, 372, 423-428.
Lee, J. T., Wheeler, T. C., Li, L., & Chin, L. S. (2008b). Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Human Molecular Genetics, 17, 906-917.
Leverenz, J. B., Hamilton, R., Tsuang, D. W., Schantz, A., Vavrek, D., Larson, E. B., … Kaye, J. (2008). Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathology (Zurich, Switzerland), 18, 220-224.
Lewy, F. (1912). Paralysis agitans. I. Pathologische Anatomie, In Handbuch Der Neurologie, Vol. 3 (pp. 920-933). Berlin: Springer-Verlag.
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., … Brundin, P. (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Medicine, 14, 501-503. https://doi.org/10.1038/nm1746
Li, W., Wu, X., Hu, X., Wang, T., Liang, S., Duan, Y., … Qin, B. (2017). Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features. Science China. Life Sciences, 60, 1223-1233.
Li, W. W., Yang, R., Guo, J. C., Ren, H. M., Zha, X. L., Cheng, J. S., & Cai, D. F. (2007). Localization of alpha-synuclein to mitochondria within midbrain of mice. NeuroReport, 18, 1543-1546.
Lindersson, E., Beedholm, R., Hojrup, P., Moos, T., Gai, W., Hendil, K. B., & Jensen, P. H. (2004). Proteasomal inhibition by alpha-synuclein filaments and oligomers. The Journal of Biological Chemistry, 279, 12924-12934.
Liu, B., Fang, F., Pedersen, N. L., Tillander, A., Ludvigsson, J. F., Ekbom, A., … Wirdefeldt, K. (2017). Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology, 88, 1996-2002. https://doi.org/10.1212/WNL.0000000000003961
Liu, C. W., Corboy, M. J., DeMartino, G. N., & Thomas, P. J. (2003). Endoproteolytic activity of the proteasome. Science, 299, 408-411. https://doi.org/10.1126/science.1079293
Lopes da Fonseca, T., Pinho, R., & Outeiro, T. F. (2016). A familial ATP13A2 mutation enhances alpha-synuclein aggregation and promotes cell death. Human Molecular Genetics, 25, 2959-2971. https://doi.org/10.1093/hmg/ddw147
Loria, F., Vargas, J. Y., Bousset, L., Syan, S., Salles, A., Melki, R., & Zurzolo, C. (2017). alpha-Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. Acta Neuropathologica, 134, 789-808.
Lothian, A., Lago, L., Mukherjee, S., Connor, A. R., Fowler, C., McLean, C. A., … Roberts, B. R. (2019). Characterization of the metal status of natively purified alpha-synuclein from human blood, brain tissue, or recombinant sources using size exclusion ICP-MS reveals no significant binding of Cu, Fe or Zn. Metallomics: Integrated Biometal Science, 11, 128-140. https://doi.org/10.1039/C8MT00223A
Lowe, J., Blanchard, A., Morrell, K., Lennox, G., Reynolds, L., Billett, M., … Mayer, R. J. (1988). Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. The Journal of Pathology, 155, 9-15. https://doi.org/10.1002/path.1711550105
Luk, K. C., Kehm, V. M., Zhang, B., O'Brien, P., Trojanowski, J. Q., & Lee, V. M. (2012). Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. The Journal of Experimental Medicine, 209, 975-986.
Luk, K. C., Song, C., O'Brien, P., Stieber, A., Branch, J. R., Brunden, K. R., … Lee, V. M. (2009). Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 20051-20056.
Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M. E., & Sidransky, E. (2004). Glucocerebrosidase mutations in subjects with parkinsonism. Molecular Genetics and Metabolism, 81(1), 70-73. https://doi.org/10.1016/j.ymgme.2003.11.004.
Maass, F., Schulz, I., Lingor, P., Mollenhauer, B., & Bahr, M. (2019). Cerebrospinal fluid biomarker for Parkinson's disease: An overview. Molecular and Cellular Neurosciences, 97, 60-66. https://doi.org/10.1016/j.mcn.2018.12.005
Magdalinou, N. K., Noyce, A. J., Pinto, R., Lindstrom, E., Holmén-Larsson, J., Holtta, M., … Gobom, J. (2017). Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 37, 65-71. https://doi.org/10.1016/j.parkreldis.2017.01.016
Mak, S. K., McCormack, A. L., Manning-Bog, A. B., Cuervo, A. M., & Di Monte, D. A. (2010). Lysosomal degradation of alpha-synuclein in vivo. The Journal of Biological Chemistry, 285, 13621-13629.
Manne, S., Kondru, N., Hepker, M., Jin, H., Anantharam, V., Lewis, M., … Kanthasamy, A. G. (2019). Ultrasensitive detection of aggregated alpha-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: New high-throughput neuroimmune biomarker assay for parkinsonian disorders. Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology, 14, 423-435.
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T. I., Yin, X., Xiong, Y., … Kang, H. C. (2016) Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 353, aah3374.
Maroteaux, L., Campanelli, J. T., & Scheller, R. H. (1988). Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 8, 2804-2815.
Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., … Lee, M. K. (2006). Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 26, 41-50.
Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A. C., Mazzulli, J., Mosharov, E. V., … Dauer, W. (2008). Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. The Journal of Clinical Investigation, 118, 777-788.
Marui, W., Iseki, E., Kato, M., & Kosaka, K. (2003). Degeneration of tyrosine hydroxylase-immunoreactive neurons in the cerebral cortex and hippocampus of patients with dementia with Lewy bodies. Neuroscience Letters, 340, 185-188. https://doi.org/10.1016/S0304-3940(03)00101-0
Marvian, A. T., Koss, D. J., Aliakbari, F., Morshedi, D., & Outeiro, T. F. (2019). In vitro models of synucleinopathies: Informing on molecular mechanisms and protective strategies. Journal of Neurochemistry, 150, 535-565.
Masaracchia, C., Hnida, M., Gerhardt, E., Lopes da Fonseca, T., Villar-Pique, A., Branco, T., … Outeiro, T. F. (2018). Membrane binding, internalization, and sorting of alpha-synuclein in the cell. Acta Neuropathologica Communications, 6, 79. https://doi.org/10.1186/s40478-018-0578-1
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., … Mucke, L. (2000). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science, 287, 1265-1269.
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., … Hasegawa, M. (2013). Prion-like spreading of pathological alpha-synuclein in brain. Brain: A Journal of Neurology, 136, 1128-1138.
Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W., Röyttä, M., & Mattila, P. M. (2000). Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathologica, 100, 285-290. https://doi.org/10.1007/s004019900168
Mazzulli, J. R., Zunke, F., Isacson, O., Studer, L., & Krainc, D. (2016). alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America, 113, 1931-1936.
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., … Kosaka, K. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology, 89, 88-100. https://doi.org/10.1212/WNL.0000000000004058
McLean, P. J., Kawamata, H., & Hyman, B. T. (2001). Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience, 104, 901-912.
McLean, P. J., Kawamata, H., Ribich, S., & Hyman, B. T. (2000). Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. The Journal of Biological Chemistry, 275, 8812-8816.
Mendes, A., Gonçalves, A., Vila-Chã, N., Moreira, I., Fernandes, J., Damásio, J., … Cavaco, S. (2015). Appendectomy may delay Parkinson's disease Onset. Movement Disorders: Official Journal of the Movement Disorder Society, 30, 1404-1407. https://doi.org/10.1002/mds.26311
Merchant, K. M., Cedarbaum, J. M., Brundin, P., Dave, K. D., Eberling, J., Espay, A. J., … Weiner, D. M. (2019). A Proposed roadmap for Parkinson's disease proof of concept clinical trials investigating compounds targeting alpha-synuclein. Journal of Parkinson's Disease, 9, 31-61. https://doi.org/10.3233/JPD-181471
Milber, J. M., Noorigian, J. V., Morley, J. F., Petrovitch, H., White, L., Ross, G. W., & Duda, J. E. (2012). Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology, 79, 2307-2314. https://doi.org/10.1212/WNL.0b013e318278fe32
Mollenhauer, B., Bowman, F. D., Drake, D., Duong, J., Blennow, K., El-Agnaf, O., … Dunty, J. M. (2019a). Antibody-based methods for the measurement of alpha-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. Journal of Neurochemistry, 149, 126-138.
Mollenhauer, B., Caspell-Garcia, C. J., Coffey, C. S., Taylor, P., Singleton, A., Shaw, L. M., … Oertel, W. (2019b). Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 34, 1354-1364.
Moors, T. E., Maat, C. A., Niedieker, D., Mona, D., Petersen, D., Timmermans-Huisman, E., … Mundigl, O. (2018). Detailed structural orchestration of Lewy pathology in Parkinson’s disease as revealed by 3D multicolor. STED Microscopy. Biorxiv, 470476.
Nakhjavani, M., Morteza, A., Khajeali, L., Esteghamati, A., Khalilzadeh, O., Asgarani, F., & Outeiro, T. F. (2010). Increased serum HSP70 levels are associated with the duration of diabetes. Cell Stress and Chaperones, 15, 959-964. https://doi.org/10.1007/s12192-010-0204-z
Nathan, J. A., Kim, H. T., Ting, L., Gygi, S. P., & Goldberg, A. L. (2013). Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? The EMBO Journal, 32, 552-565. https://doi.org/10.1038/emboj.2012.354
Oaks, A. W., Marsh-Armstrong, N., Jones, J. M., Credle, J. J., & Sidhu, A. (2013). Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking. PLoS ONE, 8, e70872. https://doi.org/10.1371/journal.pone.0070872
O'Farrell, C., Murphy, D. D., Petrucelli, L., Singleton, A. B., Hussey, J., Farrer, M., … Cookson, M. R. (2001). Transfected synphilin-1 forms cytoplasmic inclusions in HEK293 cells. Brain Research. Molecular Brain Research, 97, 94-102. https://doi.org/10.1016/S0169-328X(01)00292-3
Olsen, A. L., & Feany, M. B. (2019). Glial alpha-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo. Glia, 67, 1933-1957.
Orme, T., Guerreiro, R., & Bras, J. (2018). The genetics of dementia with Lewy bodies: Current understanding and future directions. Current Neurology and Neuroscience Reports, 18, 67. https://doi.org/10.1007/s11910-018-0874-y
Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., & Torizuka, T. (2005). Microglial activation and dopamine terminal loss in early Parkinson's disease. Annals of Neurology, 57, 168-175. https://doi.org/10.1002/ana.20338
Oueslati, A. (2016). Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: What have we learned in the last decade? Journal of Parkinson's Disease, 6, 39-51. https://doi.org/10.3233/JPD-160779
Outeiro, T. F., Klucken, J., Strathearn, K. E., Liu, F., Nguyen, P., Rochet, J. C., … McLean, P. J. (2006). Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochemical and Biophysical Research Communications, 351, 631-638.
Outeiro, T. F., & Lindquist, S. (2003). Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science, 302, 1772-1775. https://doi.org/10.1126/science.1090439
Outeiro, T. F., & Mestre, T. A. (2019). Synuclein Meeting 2019: Where we are and where we need to go. Journal of Neurochemistry, 150, 462-466. https://doi.org/10.1111/jnc.14825
Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., … McLean, P. J. (2008). Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE, 3, e1867.
Paleologou, K. E., Oueslati, A., Shakked, G., Rospigliosi, C. C., Kim, H. Y., Lamberto, G. R., … Chiappe, D. (2010). Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 30, 3184-3198.
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., … Calabresi, P. (2014). Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease. Movement Disorders: Official Journal of the Movement Disorder Society, 29, 1019-1027. https://doi.org/10.1002/mds.25772
Peng, C., Gathagan, R. J., Covell, D. J., Medellin, C., Stieber, A., Robinson, J. L., … Trojanowski, J. Q. (2018). Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature, 557, 558-563.
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002). A role for alpha-synuclein in the regulation of dopamine biosynthesis. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 22, 3090-3099.
Pinho, R., Paiva, I., Jerčić, K. G., Fonseca-Ornelas, L., Gerhardt, E., Fahlbusch, C., … Outeiro, T. F. (2019). Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. Human Molecular Genetics, 28, 31-50. https://doi.org/10.1093/hmg/ddy326
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., … Stenroos, E. S. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
Porro, C., Panaro, M. A., Lofrumento, D. D., Hasalla, E., & Trotta, T. (2019). The multiple roles of exosomes in Parkinson's disease: An overview. Immunopharmacology and Immunotoxicology, 41, 469-476. https://doi.org/10.1080/08923973.2019.1650371
Poulopoulos, M., Levy, O. A., & Alcalay, R. N. (2012). The neuropathology of genetic Parkinson's disease. Movement Disorders, 27(7), 811-933. https://doi.org/10.1002/mds.24962.
Prusiner, S. B. (1991). Molecular biology of prion diseases. Science, 252, 1515-1522. https://doi.org/10.1126/science.1675487
Prusiner, S. B., Woerman, A. L., Mordes, D. A., Watts, J. C., Rampersaud, R., Berry, D. B., … Geschwind, D. H. (2015). Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proceedings of the National Academy of Sciences of the United States of America, 112, E5308-5317.
Qiao, L., Hamamichi, S., Caldwell, K. A., Caldwell, G. A., Yacoubian, T. A., Wilson, S., … Zhang, J. (2008). Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Molecular Brain, 1, 17. https://doi.org/10.1186/1756-6606-1-17
Qing, H., Zhang, Y., Deng, Y., McGeer, E. G., & McGeer, P. L. (2009). Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochemical and Biophysical Research Communications, 390, 1229-1234.
Rasia, R. M., Bertoncini, C. W., Marsh, D., Hoyer, W., Cherny, D., Zweckstetter, M., … Fernandez, C. O. (2005). Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 102, 4294-4299.
Rodriguez, L., Marano, M. M., & Tandon, A. (2018). Import and export of misfolded alpha-synuclein. Frontiers in Neuroscience, 12, 344.
Rott, R., Szargel, R., Haskin, J., Shani, V., Shainskaya, A., Manov, I., … Engelender, S. (2008). Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. The Journal of Biological Chemistry, 283, 3316-3328.
Rott, R., Szargel, R., Shani, V., Hamza, H., Savyon, M., Abd Elghani, F., … Engelender, S. (2017). SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation. Proceedings of the National Academy of Sciences of the United States of America, 114, 13176-13181.
Roy, S., & Wolman, L. (1969). Ultrastructural observations in Parkinsonism. The Journal of Pathology, 99, 39-44. https://doi.org/10.1002/path.1710990106
Sacino, A. N., Brooks, M. M., Chakrabarty, P., Saha, K., Khoshbouei, H., Golde, T. E., & Giasson, B. I. (2017). Proteolysis of alpha-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. Journal of Neurochemistry, 140, 662-678.
Sahin, C., Lorenzen, N., Lemminger, L., Christiansen, G., Møller, I. M., Vesterager, L. B., … Otzen, D. E. (2017). Antibodies against the C-terminus of α-synuclein modulate its fibrillation. Biophysical Chemistry, 220, 34-41.
Saijo, E., Groveman, B. R., Kraus, A., Metrick, M., Orru, C. D., Hughson, A. G., & Caughey, B. (2019). Ultrasensitive RT-QuIC seed amplification assays for disease-associated tau, alpha-synuclein, and prion aggregates. Methods in Molecular Biology, 1873, 19-37.
Salvador, N., Aguado, C., Horst, M., & Knecht, E. (2000). Import of a cytosolic protein into lysosomes by chaperone-mediated autophagy depends on its folding state. The Journal of Biological Chemistry, 275, 27447-27456. https://doi.org/10.1074/jbc.M001394200
Schaser, A. J., Osterberg, V. R., Dent, S. E., Stackhouse, T. L., Wakeham, C. M., Boutros, S. W., … Unni, V. K. (2019). Alpha-synuclein is a DNA binding protein that modulates DNA repair with implications for Lewy body disorders. Scientific Reports, 9, 10919. https://doi.org/10.1038/s41598-019-47227-z
Schlossmacher, M. G., Frosch, M. P., Gai, W. P., Medina, M., Sharma, N., Forno, L., … Kosik, K. S. (2002). Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. The American Journal of Pathology, 160, 1655-1667. https://doi.org/10.1016/S0002-9440(10)61113-3
Schmid, A. W., Fauvet, B., Moniatte, M., & Lashuel, H. A. (2013). Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Molecular and Cellular Proteomics: MCP, 12, 3543-3558. https://doi.org/10.1074/mcp.R113.032730
Scott, D. A., Tabarean, I., Tang, Y., Cartier, A., Masliah, E., & Roy, S. (2010). A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 30, 8083-8095.
Shahmoradian, S. H., Lewis, A. J., Genoud, C., Hench, J., Moors, T. E., Navarro, P. P., … Lauer, M. E. (2019). Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. Nature Neuroscience, 22, 1099-1109. https://doi.org/10.1038/s41593-019-0423-2
Shavali, S., Brown-Borg, H. M., Ebadi, M., & Porter, J. (2008). Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neuroscience Letters, 439, 125-128. https://doi.org/10.1016/j.neulet.2008.05.005
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., … Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England Journal of Medicine, 361(17), 1651-1656. https://doi.org/10.1056/NEJMoa0901281.
Spencer, B., Valera, E., Rockenstein, E., Overk, C., Mante, M., Adame, A., … Games, D. (2017). Anti-alpha-synuclein immunotherapy reduces alpha-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathologica Communications, 5, 7.
Spencer, B., Williams, S., Rockenstein, E., Valera, E., Xin, W., Mante, M., … Sierks, M. R. (2016). α-Synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Ann Clin Transl Neurol, 3, 588-606.
Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997). Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
Svensson, E., Horvath-Puho, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sorensen, H. T. (2015). Vagotomy and subsequent risk of Parkinson's disease. Annals of Neurology, 78, 522-529. https://doi.org/10.1002/ana.24448
Swant, J., Goodwin, J. S., North, A., Ali, A. A., Gamble-George, J., Chirwa, S., & Khoshbouei, H. (2011). alpha-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. The Journal of Biological Chemistry, 286, 43933-43943.
Szegő, É. M., Dominguez-Meijide, A., Gerhardt, E., König, A., Koss, D. J., Li, W., … Outeiro, T. F. (2019). Cytosolic trapping of a mitochondrial heat shock protein is an early pathological event in synucleinopathies. Cell Reports, 28(65-77), e66. https://doi.org/10.1016/j.celrep.2019.06.009
Tanaka, M., Kim, Y. M., Lee, G., Junn, E., Iwatsubo, T., & Mouradian, M. M. (2004). Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. The Journal of Biological Chemistry, 279, 4625-4631.
Tenreiro, S., Reimão-Pinto, M. M., Antas, P., Rino, J., Wawrzycka, D., Macedo, D., … Outeiro, T. F. (2014). Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genetics, 10, e1004302. https://doi.org/10.1371/journal.pgen.1004302
Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., … El-Agnaf, O. M. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochemical and Biophysical Research Communications, 349, 162-166.
Uversky, V. N. (2003). A protein-chameleon: Conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. Journal of Biomolecular Structure and Dynamics, 21, 211-234.
Vaikath, N. N., Hmila, I., Gupta, V., Erskine, D., Ingelsson, M., & El-Agnaf, O. M. A. (2019). Antibodies against alpha-synuclein: Tools and therapies. Journal of Neurochemistry, 150, 612-625. https://doi.org/10.1111/jnc.14713
Vaikath, N. N., Majbour, N. K., Paleologou, K. E., Ardah, M. T., van Dam, E., van de Berg, W. D. J., … El-Agnaf, O. M. A. (2015). Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Neurobiology of Disease, 79, 81-99. https://doi.org/10.1016/j.nbd.2015.04.009
Vasili, E., Dominguez-Meijide, A., & Outeiro, T. F. (2019). Spreading of alpha-Synuclein and Tau: A systematic comparison of the mechanisms involved. Frontiers in Molecular Neuroscience, 12, 107.
Verdurand, M., Levigoureux, E., Zeinyeh, W., Berthier, L., Mendjel-Herda, M., Cadarossanesaib, F., … Chauveau, F. (2018). In silico, in vitro, and in vivo evaluation of new candidates for alpha-synuclein PET imaging. Molecular Pharmaceutics, 15, 3153-3166.
Vicente Miranda, H., Cássio, R., Correia-Guedes, L., Gomes, M. A., Chegão, A., Miranda, E., … Outeiro, T. F. (2017a). Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. Scientific Reports, 7, 13713. https://doi.org/10.1038/s41598-017-14175-5
Vicente Miranda, H., Szego, E. M., Oliveira, L. M. A., Breda, C., Darendelioglu, E., de Oliveira, R. M., … Munari, F. (2017b). Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain: A Journal of Neurology, 140, 1399-1419.
Villar-Pique, A., Lopes da Fonseca, T., Sant'Anna, R., Szegö, É. M., Fonseca-Ornelas, L., Pinho, R., … Rossetti, G. (2016). Environmental and genetic factors support the dissociation between alpha-synuclein aggregation and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 113, E6506-E6515.
Vogiatzi, T., Xilouri, M., Vekrellis, K., & Stefanis, L. (2008). Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. The Journal of Biological Chemistry, 283, 23542-23556.
Volpicelli-Daley, L. A., Gamble, K. L., Schultheiss, C. E., Riddle, D. M., West, A. B., & Lee, V. M. (2014). Formation of alpha-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. Molecular Biology of the Cell, 25, 4010-4023.
Wakabayashi, K., Engelender, S., Yoshimoto, M., Tsuji, S., Ross, C. A., & Takahashi, H. (2000). Synphilin-1 is present in Lewy bodies in Parkinson's disease. Annals of Neurology, 47, 521-523. https://doi.org/10.1002/1531-8249(200004)47:4<521:AID-ANA18>3.0.CO;2-B
Wakabayashi, K., Hansen, L. A., & Masliah, E. (1995). Cortical Lewy body-containing neurons are pyramidal cells: Laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathologica, 89, 404-408. https://doi.org/10.1007/BF00307643
Wakabayashi, K., Tanji, K., Odagiri, S., Miki, Y., Mori, F., & Takahashi, H. (2013). The Lewy body in Parkinson's disease and related neurodegenerative disorders. Molecular Neurobiology, 47, 495-508. https://doi.org/10.1007/s12035-012-8280-y
Walsh, N. C., Kenney, L. L., Jangalwe, S., Aryee, K. E., Greiner, D. L., Brehm, M. A., & Shultz, L. D. (2017). Humanized mouse models of clinical disease. Annual Review of Pathology, 12, 187-215. https://doi.org/10.1146/annurev-pathol-052016-100332
Wang, Q., Liu, Y., & Zhou, J. (2015). Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Translational Neurodegeneration, 4, 19. https://doi.org/10.1186/s40035-015-0042-0
Wersinger, C., Rusnak, M., & Sidhu, A. (2006). Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. The European Journal of Neuroscience, 24, 55-64. https://doi.org/10.1111/j.1460-9568.2006.04900.x
Xilouri, M., Brekk, O. R., Polissidis, A., Chrysanthou-Piterou, M., Kloukina, I., & Stefanis, L. (2016). Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy, 12, 2230-2247. https://doi.org/10.1080/15548627.2016.1214777
Xiong, Y., & Yu, J. (2018). Modeling Parkinson's disease in Drosophila: What have we learned for dominant traits? Frontiers in Neurology, 9, 228. https://doi.org/10.3389/fneur.2018.00228
Yan, J. Q., Yuan, Y. H., Chu, S. F., Li, G. H., & Chen, N. H. (2018). E46K mutant alpha-synuclein is degraded by both proteasome and macroautophagy pathway. Molecules, 23, 2839.
Yin, G., Lopes da Fonseca, T., Eisbach, S. E., Anduaga, A. M., Breda, C., Orcellet, M. L., … Fernandez, C. O. (2014). alpha-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. Neurobiology of Disease, 70, 149-161.
Yu, S., Zuo, X., Li, Y., Zhang, C., Zhou, M., Zhang, Y. A., … Chan, P. (2004). Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neuroscience Letters, 367, 34-39.
Zaltieri, M., Grigoletto, J., Longhena, F., Navarria, L., Favero, G., Castrezzati, S., … Bellucci, A. (2015). alpha-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. Journal of Cell Science, 128, 2231-2243. https://doi.org/10.1242/jcs.157867
Zhu, X., Babar, A., Siedlak, S. L., Yang, Q., Ito, G., Iwatsubo, T., … Chen, S. G. (2006). LRRK2 in Parkinson's disease and dementia with Lewy bodies. Molecular Neurodegeneration, 1, 17.
Zigoneanu, I. G., Yang, Y. J., Krois, A. S., Haque, E., & Pielak, G. J. (2012). Interaction of alpha-synuclein with vesicles that mimic mitochondrial membranes. Biochimica Et Biophysica Acta, 1818, 512-519.
Zondler, L., Miller-Fleming, L., Repici, M., Gonçalves, S., Tenreiro, S., Rosado-Ramos, R., … Outeiro, T. F. (2014). DJ-1 interactions with alpha-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. Cell Death & Disease, 5, e1350.